
  
    
      
        Background_NNP
        Dilated_NNP cardiomyopathy_NN (_( DCM_NNP )_) is_VBZ a_DT disorder_NN characterized_VBN
        by_IN four-chamber_JJ dilation_NN of_IN the_DT heart_NN ._. DCM_NNP is_VBZ often_RB
        progressive_JJ and_CC results_NNS in_IN reduced_VBN heart_NN function_NN and_CC
        congestive_JJ heart_NN failure_NN ._. Although_IN etiologically_RB diverse_JJ ,_,
        inheritance_NN is_VBZ a_DT significant_JJ contributor_NN to_TO the_DT development_NN
        of_IN DCM_NNP ._. Supporting_VBG this_DT ,_, mutations_NNS in_IN a_DT number_NN of_IN different_JJ
        genes_NNS have_VBP recently_RB been_VBN associated_VBN with_IN familial_NN forms_NNS of_IN
        DCM_NNP [_NN 2_CD ]_NN ,_, and_CC mutations_NNS in_IN the_DT gene_NN encoding_VBG lamin_NN A_DT /_NN C_NNP
        appear_VBP to_TO be_VB a_DT significant_JJ component_NN ._. Lamins_NNP A_DT and_CC C_NNP are_VBP
        two_CD different_JJ proteins_NNS produced_VBN by_IN alternative_NN splicing_VBG
        from_IN the_DT same_JJ gene_NN ._. They_PRP are_VBP identical_JJ along_IN their_PRP$ first_JJ
        566_CD amino_JJ acids_NNS and_CC differ_VB only_RB in_IN their_PRP$ carboxyl_NN terminus_JJ ._.
        As_IN specialized_JJ proteins_NNS of_IN the_DT intermediate_JJ filament_NN
        protein_NN family_NN ,_, lamin_NN A_DT /_NN C_NNP is_VBZ found_VBN at_IN the_DT inner_JJ nuclear_JJ
        membrane_NN where_WRB it_PRP forms_VBZ a_DT scaffold_NN that_IN interacts_NNS with_IN a_DT
        network_NN of_IN membrane_NN bound_VBN and_CC nucleoplasmic_JJ proteins_NNS in_IN
        addition_NN to_TO chromatin_NN [_NN 3_CD 4_CD 5_CD ]_NN ._. Mutations_NNP in_IN the_DT gene_NN
        encoding_VBG the_DT nuclear_JJ membrane_NN protein_NN emerin_NN produce_NN
        autosomal_NN recessive_JJ Emery_NNP Dreifuss_NNP Muscular_NNP Dystrophy_NNP ,_, a_DT
        disorder_NN that_IN phenotypically_RB overlaps_NNS the_DT neuromuscular_NN and_CC
        cardiovascular_JJ features_NNS seen_VBN with_IN lamin_NN A_DT /_NN C_NNP mutations_NNS [_NN 6_CD ]_NN
        ._. Consistent_NNP with_IN this_DT ,_, lamin_NN A_DT /_NN C_NNP directly_RB binds_NNS emerin_NN [_NN 7_CD
        8_CD ]_NN ._. Lamins_NNP A_DT and_CC C_NNP are_VBP broadly_RB expressed_VBN in_IN many_JJ
        different_JJ cell_NN types_NNS and_CC are_VBP primarily_RB expressed_VBN in_IN
        terminally_RB differentiated_JJ cells_NNS ._. It_PRP is_VBZ not_RB known_VBN how_WRB
        mutations_NNS in_IN 
        LMNA_NNP lead_VBP to_TO tissue-specific_JJ
        phenotypes_NNS ._.
        The_DT first_JJ autosomal_NN dominant_JJ form_NN of_IN cardiomyopathy_NN was_VBD
        mapped_VBN in_IN 1994_CD to_TO the_DT centromeric_JJ region_NN of_IN chromosome_NN 1_CD [_NN
        9_CD ]_NN ._. Linkage_NNP was_VBD achieved_VBN using_VBG genetic_JJ and_CC clinical_JJ
        material_NN from_IN a_DT large_JJ ,_, well-characterized_JJ kindred_JJ [_NN 1_CD ]_NN ._.
        One_CD of_IN the_DT striking_JJ characteristics_NNS from_IN this_DT family_NN was_VBD
        the_DT degree_NN of_IN cardiac_JJ conduction_NN system_NN disease_NN that_IN
        primarily_RB targeted_VBD the_DT atrioventricular_NN node_NN [_NN 1_CD 10_CD ]_NN ._.
        Many_JJ members_NNS of_IN the_DT kindred_JJ exhibited_VBN sick_JJ sinus_JJ syndrome_NN ,_,
        atrial_NN fibrillation_NN and_CC sudden_JJ death_NN ._.
        In_IN addition_NN to_TO DCM_NNP with_IN conduction_NN system_NN disease_NN and_CC
        variable_JJ skeletal_NN muscle_NN involvement_NN ,_, mutations_NNS in_IN the_DT
        Lamin_NNP A_DT /_NN C_NNP gene_NN [_NN OMIM_NNP 150330_CD ]_NN have_VBP been_VBN shown_VBN to_TO cause_VB
        autosomal_NN dominant_JJ [_NN 11_CD ]_NN and_CC autosomal_NN recessive_JJ [_NN 12_CD ]_NN
        Emery-_NNP Dreifuss_NNP Muscular_NNP Dystrophy_NNP (_( EDMD_NNP )_) ,_, autosomal_NN
        dominant_JJ limb-girdle_JJ muscular_JJ dystrophy_NN type_NN 1_CD B_NNP (_( LGMD_NNP )_) [_NN 13_CD
        ]_NN ,_, autosomal_NN recessive_JJ type_NN 2_CD Charcot-_NNP Marie_NNP Tooth_NNP type_NN 2_CD [_NN
        14_CD ]_NN ,_, familial_NN partial_JJ lipodystrophy_NN [_NN 15_CD 16_CD ]_NN ,_,
        Mandibuloacral_NNP dysplasia_NN [_NN 17_CD ]_NN and_CC Hutchinson-_NNP Gilford_NNP
        progeria_NN [_NN 18_CD ]_NN ._. The_DT phenotypic_JJ spectrum_NN from_IN DCM_NNP to_TO EDMD_NNP
        and_CC limb_NN girdle_NN muscular_JJ dystrophy_NN appears_VBZ continuous_JJ ._.
        However_RB ,_, the_DT mechanism_NN by_IN which_WDT 
        LMNA_NNP mutations_NNS lead_VBP to_TO cardiac_JJ versus_CC
        skeletal_NN muscle_NN disease_NN is_VBZ unknown_JJ ._.
        We_PRP now_RB evaluated_VBD a_DT woman_NN with_IN DCM_NNP and_CC sinus_JJ bradycardia_NN ._.
        Her_PRP$ immediate_JJ family_NN history_NN was_VBD significant_JJ for_IN
        symptomatic_JJ bradycardia_NN requiring_VBG pacemaker_NN implantation_NN ._.
        She_PRP is_VBZ a_DT member_NN of_IN the_DT kindred_JJ initially_RB described_VBN by_IN
        Graber_NNP 
        et_CC al_NN [_NN 1_CD ]_NN ._. We_PRP screened_VBD this_DT
        individual_NN for_IN mutations_NNS and_CC found_VBD a_DT novel_NN mutation_NN in_IN exon_NN
        5_CD of_IN 
        LMNA_NNP ._. This_DT two_CD bp_NN deletion_NN is_VBZ
        predicted_VBN to_TO disrupt_VB the_DT reading_NN frame_NN and_CC produce_VB a_DT
        truncated_JJ lamin_NN A_DT and_CC C_NNP ._.
      
      
        Methods_NNP
        
          Patient_NNP recruitment_NN
          Written_VBN and_CC informed_VBN consent_NN was_VBD obtained_VBN in_IN
          accordance_NN with_IN the_DT University_NNP of_IN Chicago_NNP 's_POS Institutional_NNP
          Review_NNP Board_NNP ._. Clinical_NNP data_NNS were_VBD obtained_VBN through_IN
          evaluations_NNS performed_VBN at_IN the_DT University_NNP of_IN Chicago_NNP ._.
        
        
          Genetic_NNP Analysis_NNP
          DNA_NN extraction_NN from_IN blood_NN was_VBD performed_VBN using_VBG PureGene_NNP
          according_VBG to_TO the_DT manufacturer_NN 's_POS recommendations_NNS ._. PCR_NNP
          primers_NNS were_VBD designed_VBN to_TO amplify_VB all_DT twelve_CD protein_NN
          coding_VBG exons_NNS of_IN 
          LMNA_NNP (_( Table_NNP I_PRP )_) ._. DHPLC_NNP analysis_NN of_IN
          each_DT exon_NN was_VBD carried_VBN out_IN on_IN a_DT WAVE_NNP ™_NN (_( Transgenomic_NNP )_) ;_: exon_NN
          5_CD was_VBD analyzed_VBN at_IN 65_CD ._. 2_LS °_NN C_NNP with_IN 51_CD %_NN -_: 56_CD %_NN -_: 65_CD %_NN acetonitrile_NN ._.
          SSCP_NNP was_VBD performed_VBN using_VBG MDE_NNP ™_NN (_( FMC_NNP )_) as_IN described_VBN [_NN 19_CD ]_NN ._.
          Direct_NNP sequencing_VBG of_IN PCR_NNP products_NNS was_VBD completed_VBN using_VBG
          cycle_NN sequencing_VBG ._. To_TO confirm_VB the_DT presence_NN of_IN the_DT
          mutation_NN ,_, PCR_NNP products_NNS were_VBD purified_JJ and_CC digested_VBN with_IN
          AlwN_NNP I_PRP ._.
        
      
      
        Results_NNS
        
          Phenotype_NNP Analysis_NNP
          A_DT 45_CD year-old_JJ Caucasian_NNP woman_NN with_IN a_DT history_NN of_IN
          paroxysmal_JJ atrial_NN fibrillation_NN ,_, sick_JJ sinus_JJ syndrome_NN ,_,
          dilated_JJ cardiomyopathy_NN ,_, and_CC fatigue_NN was_VBD seen_VBN in_IN the_DT
          University_NNP of_IN Chicago_NNP 's_POS Cardiovascular_NNP Genetics_NNP Clinic_NNP
          for_IN evaluation_NN and_CC treatment_NN ._. The_DT patient_NN is_VBZ a_DT member_NN of_IN
          a_DT large_JJ kindred_JJ previously_RB described_VBD [_NN 1_CD 9_CD 10_CD ]_NN ._. The_DT
          patient_NN was_VBD evaluated_VBN by_IN EKG_NNP (_( Figure_NN 1_LS )_) that_WDT demonstrated_VBD
          marked_VBD sinus_JJ bradycardia_NN and_CC first_JJ degree_NN
          atrioventricular_NN block_NN ._. An_DT echocardiogram_NN showed_VBD moderate_JJ
          dilation_NN of_IN the_DT left_NN ventricle_NN (_( 5_CD ._. 3_LS cm_NN end_NN diastolic_JJ
          internal_JJ diameter_NN )_) and_CC mild_JJ dilation_NN of_IN the_DT right_JJ
          ventricle_NN ._. The_DT left_VBN ventricular_NN performance_NN was_VBD estimated_VBN
          as_IN the_DT lower_JJR end_NN of_IN normal_JJ with_IN a_DT normal_JJ fractional_JJ
          shortening_NN (_( 42_CD %_NN )_) (_( Figure_NN 2_LS )_) ._. The_DT patient_NN reported_VBD no_DT
          neuromuscular_NN complaints_NNS ,_, and_CC on_IN physical_JJ exam_NN showed_VBD no_DT
          overt_JJ muscle_NN weakness_NN ._.
          The_DT pedigree_NN for_IN this_DT proband_NN is_VBZ shown_VBN in_IN Figure_NN 3_CD ._.
          All_DT affected_VBN individuals_NNS had_VBD undergone_VBN pacemaker_NN
          implantation_NN for_IN symptomatic_JJ bradycardia_NN ._. Her_PRP$ mother_NN
          reported_VBD fatigue_NN and_CC was_VBD also_RB noted_VBN to_TO have_VB an_DT abnormal_JJ
          skeletal_NN muscle_NN biopsy_NN ._. Because_IN of_IN her_PRP$ marked_JJ fatigue_NN and_CC
          family_NN history_NN of_IN sudden_JJ death_NN ,_, a_DT dual_JJ chamber_NN pacemaker_NN
          and_CC automatic_JJ defibrillator_NN were_VBD implanted_VBN ._. Of_IN note_NN ,_, the_DT
          proband_NN reported_VBD an_DT improvement_NN in_IN her_PRP$ fatigue_NN symptoms_NNS
          after_IN pacer_NN implantation_NN ._. With_IN pacemaker_NN implantation_NN ,_,
          her_PRP$ baseline_NN heart_NN rate_NN improved_VBN from_IN 40_CD bpm_NN to_TO 80_CD
          bpm_NN ._.
        
        
          Genotype_NNP Analysis_NNP
          All_DT twelve_CD exons_NNS of_IN 
          LMNA_NNP were_VBD screened_VBD by_IN denaturing_VBG
          high_JJ performance_NN liquid_JJ chromatography_NN (_( DHPLC_NNP )_) and_CC single_JJ
          strand_NN conformation_NN polymorphism_NN (_( SSCP_NNP )_) (_( Figure_NN 4_LS )_) ._. In_IN
          exon_NN 5_CD ,_, a_DT two_CD bp_NN (_( CT_NNP )_) deletion_NN was_VBD detected_VBN in_IN the_DT 
          LMNA_NNP gene_NN (_( Figure_NN 5_LS )_) ._. The_DT two_CD bp_NN
          deletion_NN falls_VBZ into_IN positions_NNS 908_CD and_CC 909_CD of_IN the_DT NCBI_NNP
          Accession_NNP #_# NM_NNP __NN 170708_CD where_WRB 1_CD is_VBZ the_DT first_JJ coding_VBG
          nucleotide_NN ._. This_DT frameshift_NN mutation_NN is_VBZ expected_VBN to_TO
          disrupt_VB the_DT lamin_NN A_DT and_CC C_NNP sequences_NNS after_IN the_DT first_JJ 302_CD
          amino_JJ acids_NNS ._. In_IN addition_NN ,_, 26_CD novel_NN amino_JJ acids_NNS
          (_( CPAQPAPEAAGSQGGEASRPGGLTGP_NNP )_) are_VBP added_VBN after_IN the_DT
          truncation_NN ._. The_DT relatively_RB high_JJ proline_NN content_NN of_IN this_DT
          additional_JJ sequence_NN and_CC the_DT positioning_NN of_IN this_DT
          truncation_NN would_MD be_VB expected_VBN to_TO disrupt_VB the_DT second_JJ half_NN
          of_IN the_DT coiled-coil_JJ region_NN of_IN the_DT protein_NN ._. An_DT additional_JJ
          98_CD unrelated_JJ subjects_NNS with_IN dilated_JJ cardiomyopathy_NN were_VBD
          screened_VBD by_IN SSCP_NNP and_CC DHPLC_NNP and_CC found_VBD not_RB to_TO carry_VB the_DT
          908_CD __NN 909_CD delCT_NN mutation_NN ._. Finally_RB ,_, 100_CD chromosomes_NNS from_IN
          control_NN DNA_NNP samples_NNS were_VBD checked_VBN and_CC found_VBN not_RB to_TO carry_VB
          the_DT 908_CD __NN 909_CD delCT_NN mutation_NN ._.
        
      
      
        Discussion_NNP
        Our_PRP$ findings_NNS demonstrate_VBP a_DT novel_NN mutation_NN in_IN lamin_NN A_DT /_NN C_NNP
        in_IN a_DT proband_NN whose_WP$ family_NN was_VBD previously_RB linked_VBN to_TO DCM_NNP with_IN
        conduction_NN disease_NN and_CC chromosome_NN 1_CD q_NN 21_CD ._. 2_LS locus_JJ [_NN 9_CD ]_NN ._.
        Mutations_NNP in_IN the_DT 
        LMNA_NNP gene_NN associated_VBN with_IN DCM_NNP have_VBP a_DT
        more_RBR severe_JJ prognosis_NN and_CC higher-event_JJ rates_NNS compared_VBN to_TO
        individuals_NNS with_IN DCM_NNP that_WDT do_VBP not_RB have_VB 
        LMNA_NNP mutations_NNS [_NN 20_CD ]_NN ._. A_DT recent_JJ
        report_NN describing_VBG another_DT family_NN with_IN a_DT 
        LMNA_NNP mutation_NN causing_VBG DCM_NNP and_CC
        conduction_NN system_NN disease_NN documents_VBZ the_DT need_NN for_IN permanent_JJ
        pacemaker_NN implantation_NN [_NN 21_CD ]_NN ._. Previous_JJ reports_NNS on_IN the_DT
        proband_NN 's_POS kindred_JJ support_NN a_DT high-event_JJ rate_NN in_IN family_NN
        members_NNS often_RB resulting_VBG in_IN sudden_JJ cardiac_JJ death_NN even_RB in_IN
        family_NN members_NNS with_IN permanent_JJ pacemakers_NNS [_NN 10_CD ]_NN ._. For_IN
        example_NN ,_, ten_CD out_IN of_IN 38_CD family_NN members_NNS with_IN pacemakers_NNS for_IN
        high-grade_JJ atrioventricular_NN block_NN died_VBD suddenly_RB ._. Subjects_NNP
        with_IN 
        LMNA_NNP mutations_NNS should_MD be_VB carefully_RB
        evaluated_VBN for_IN both_DT pacemakers_NNS and_CC defibrillators_NNS ._.
        It_PRP is_VBZ presently_RB unknown_JJ whether_IN autosomal_NN dominant_JJ lamin_NN
        A_DT /_NN C_NNP mutations_NNS impart_VB their_PRP$ phenotype_NN through_IN dominant_JJ
        negative_NN or_CC haploinsufficient_NN mechanisms_NNS ._. The_DT majority_NN of_IN
        reported_VBD 
        LMNA_NNP mutations_NNS are_VBP missense_NN ._. In_IN this_DT
        case_NN ,_, the_DT mutant_JJ protein_NN is_VBZ thought_VBN to_TO be_VB expressed_VBN and_CC to_TO
        act_VB through_IN a_DT dominant_JJ interfering_VBG mechanism_NN ._. A_DT smaller_JJR
        number_NN of_IN 
        LMNA_NNP mutations_NNS are_VBP frameshifting_VBG and_CC
        are_VBP expected_VBN to_TO create_VB truncated_JJ lamin_NN A_DT and_CC C_NNP ._. In_IN at_IN least_JJS
        one_CD case_NN ,_, a_DT nonsense_NN mutation_NN at_IN amino_JJ acid_NN position_NN 6_CD was_VBD
        described_VBN [_NN 11_CD ]_NN ._. This_DT mutation_NN is_VBZ effectively_RB a_DT null_NN
        allele_NN and_CC therefore_RB ,_, dominant_JJ mutations_NNS ,_, at_IN least_JJS in_IN this_DT
        case_NN ,_, would_MD be_VB expected_VBN to_TO arise_VB from_IN haploinsufficiency_NN of_IN
        lamin_NN A_DT /_NN C_NNP ._. Of_IN note_NN ,_, mice_NNS with_IN a_DT null_NN allele_NN in_IN 
        lmna_NN display_NN a_DT phenotype_NN only_RB in_IN the_DT
        homozygous_JJ state_NN [_NN 22_CD ]_NN ._. The_DT mutation_NN we_PRP now_RB describe_VBP is_VBZ
        predicted_VBN to_TO generate_VB a_DT substantial_JJ protein_NN fragment_NN
        consisting_VBG of_IN the_DT first_JJ 37_CD KDa_NNP of_IN lamin_NN A_DT /_NN C_NNP ._. The_DT novel_NN ,_,
        proline-rich_JJ sequence_NN that_WDT is_VBZ predicted_VBN at_IN the_DT carboxyl_NN
        terminus_JJ of_IN the_DT truncated_JJ lamin_NN A_DT /_NN C_NNP may_MD further_RB interfere_VB
        with_IN lamin_NN function_NN ._. Lamins_NNP assemble_VB into_IN a_DT higher_JJR order_NN
        structure_NN and_CC truncations_NNS may_MD interfere_VB with_IN this_DT assembly_NN ._.
        The_DT presence_NN of_IN aberrantly_RB assembled_VBN lamin_NN filaments_NNS may_MD
        also_RB interfere_VB with_IN other_JJ lamin-interacting_JJ proteins_NNS such_JJ
        as_IN emerin_NN or_CC nesprin-_NN 1_CD α_NN [_NN 23_CD ]_NN ._.
        The_DT exact_JJ mechanism_NN by_IN which_WDT 
        LMNA_NNP mutations_NNS cause_VBP disease_NN is_VBZ not_RB
        clearly_RB elucidated_JJ at_IN this_DT time_NN ._. However_RB ,_, it_PRP is_VBZ clear_JJ that_IN
        mutations_NNS in_IN 
        LMNA_NNP cause_VB tissue-specific_JJ disease_NN
        affecting_VBG various_JJ differentiated_JJ cells_NNS including_VBG cardiac_JJ
        and_CC skeletal_NN muscle_NN ,_, adipocytes_NNS and_CC neurons_NNS ._. This_DT suggests_VBZ
        that_DT lamin_NN 's_POS role_NN at_IN the_DT nuclear_JJ membrane_NN affects_VBZ both_DT
        cell-type_JJ and_CC tissue-specific_JJ processes_NNS ._. Currently_RB ,_, there_RB
        are_VBP at_IN least_JJS two_CD theories_NNS regarding_VBG the_DT effects_NNS of_IN 
        LMNA_NNP [_NN 24_CD ]_NN ._. The_DT first_JJ postulates_NNS
        that_IN disruptions_NNS of_IN the_DT inner_JJ nuclear_JJ membrane_NN affect_NN
        heterochromatin_NN scaffolding_VBG and_CC thereby_RB gene_NN expression_NN ._. In_IN
        this_DT model_NN ,_, lamin_NN A_DT /_NN C_NNP is_VBZ necessary_JJ for_IN the_DT appropriate_JJ
        expression_NN of_IN tissue-specific_JJ genes_NNS ._. The_DT second_JJ theory_NN ,_, the_DT
        mechanical_JJ stress_NN hypothesis_NNS ,_, suggests_VBZ weakness_NN in_IN the_DT
        nuclear_JJ lamina_NN leaves_VBZ certain_JJ tissues_NNS more_RBR prone_JJ to_TO damage_VB
        by_IN force_NN ._. This_DT model_NN was_VBD first_RB raised_VBD when_WRB 
        LMNA_NNP mutations_NNS were_VBD primarily_RB
        associated_VBN with_IN disorders_NNS affecting_VBG striated_JJ muscle_NN [_NN 24_CD ]_NN
        ._. Interestingly_RB ,_, the_DT preferential_JJ involvement_NN of_IN the_DT
        specialized_JJ cells_NNS of_IN the_DT cardiac_JJ conduction_NN system_NN may_MD
        support_VB less_JJR the_DT stress_NN hypothesis_NNS as_IN the_DT cells_NNS of_IN the_DT
        atrioventricular_NN node_NN are_VBP less_RBR expected_JJ to_TO undergo_VB
        considerable_JJ deformation_NN ._. The_DT additional_JJ phenotypes_NNS now_RB
        associated_VBN with_IN 
        LMNA_NNP mutations_NNS also_RB favor_VBP alternative_JJ
        mechanisms_NNS of_IN pathogenicity_NN ._.
        Conduction_NNP disease_NN preceded_VBN the_DT development_NN of_IN dilated_JJ
        cardiomyopathy_NN in_IN the_DT proband_NN 's_POS family_NN [_NN 1_CD 10_CD ]_NN ._. This_DT
        indicates_VBZ the_DT necessity_NN for_IN careful_JJ documentation_NN of_IN a_DT
        three-generation_JJ pedigree_NN in_IN the_DT evaluation_NN of_IN patients_NNS
        with_IN conduction_NN system_NN disease_NN paying_VBG particular_JJ attention_NN
        to_TO sudden_JJ death_NN ,_, arrhythmia_NN and_CC bradycardia_NN ._. Genotyping_NNP of_IN
        patients_NNS with_IN conduction_NN disease_NN and_CC DCM_NNP may_MD provide_VB
        important_JJ information_NN regarding_VBG device_NN implantation_NN ._.
        Genetic_JJ counseling_NN for_IN patients_NNS and_CC family_NN members_NNS should_MD
        always_RB accompany_VB genetic_JJ testing_NN as_IN variable_JJ expressivity_NN
        and_CC age_NN dependent_JJ penetrance_NN may_MD influence_VB clinical_JJ
        decision_NN making_VBG [_NN 25_CD ]_NN ._.
      
      
        Conclusions_NNP
        Individuals_NNS with_IN DCM_NNP and_CC conduction_NN system_NN disease_NN
        should_MD be_VB screened_VBD by_IN family_NN history_NN and_CC genetic_JJ testing_NN ._.
        Those_DT found_VBD to_TO have_VB mutations_NNS in_IN lamin_NN A_DT /_NN C_NNP should_MD be_VB
        evaluated_VBN for_IN placement_NN of_IN pacemakers_NNS and_CC automatic_JJ
        defibrillators_NNS in_IN order_NN to_TO prevent_VB the_DT sudden_JJ cardiac_JJ death_NN
        associated_VBN with_IN this_DT disease_NN ._.
      
      
        Abbreviations_NNP
        DCM_NNP ,_, dilated_JJ cardiomyopathy_NN
        EDMD_NNP ,_, Emery_NNP Dreifuss_NNP Muscular_NNP Dystrophy_NNP
        LGMD_NNP ,_, limb_NN Girdle_NNP muscular_JJ dystrophy_NN
        SSCP_NNP ,_, single_JJ strand_NN conformation_NN polymorphism_NN
        DHPLC_NNP ,_, denaturing_VBG high_JJ pressure_NN liquid_JJ
        chromatography_NN
        
        LMNA_NNP ,_, lamin_NN A_DT /_NN C_NNP gene_NN
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
      
        Authors_NNP Contributions_NNP
        HMM_NNP was_VBD responsible_JJ for_IN gathering_VBG patient_NN data_NNS ._. MRC_NNP and_CC
        JMH_NNP carried_VBD out_IN mutation_NN detection_NN ._. EMM_NNP conceived_VBD the_DT study_NN
        and_CC evaluated_VBD the_DT data_NNS ._. The_DT manuscript_NN was_VBD written_VBN and_CC
        approved_VBN by_IN all_DT authors_NNS ._.
      
    
  
